AstraZeneca CEO Soriot questions value of annual COVID boosters in healthy people Beam sheds more light on clinical hold slapped on gene-edited CAR-T Philips adds yet another ventilator recall to the docket, citing contaminated plastic July's hospital margins were among the worst of the pandemic, Kaufman Hall says Sandoz, Amneal and Rhodes join Teva in nationwide generic Adderall shortage as demand spikes Monkeypox tracker: Texas reports first U.S. death tied to the virus Codiak's $2.5M check in July isn’t enough to stave off job cuts and restructuring FDA clears BrainsWay's 2nd neurostimulation approach to depression treatment Novartis hit with Entresto patent suit from universities amid legal fight with generics makers Sanofi, seeking to stem bleeding at hemophilia A unit, gets FDA priority review for rival to Roche InterWell Health finalizes $2.4B kidney care merger to combine tech, value-based care capabilities Theranica ropes in $45M for smartphone-connected migraine modulation armband Featured Story | By Kevin Dunleavy AstraZeneca CEO Pascal Soriot told The Telegraph that annual COVID-19 booster shots are “not a good use” of taxpayer money in all people. His comments come a week after Soriot said that the company was considering getting out of the vaccine business altogether. read more |
| |
|---|
|
Top Stories By Max Bayer Beam Therapeutics is disclosing more details about a clinical hold placed on its phase 1-ready CAR-T. The FDA's questions centered on more data from controls and results from off-target editing tests. read more By Andrea Park In the months since its far-reaching Class I recall began in June 2021, Philips has racked up a handful of others for many additional ventilators and breathing support devices that weren’t covered by the original safety notice. read more By Dave Muoio Hospitals just weathered "some of the worst margins since the beginning of the COVID-19 pandemic" due to lower outpatient volumes and longer inpatient stays, Kaufman Hall wrote in its July report. read more By Fraiser Kansteiner Alongside Teva, Amneal Pharmaceutical, Purdue subsidiary Rhodes Pharmaceuticals and Novartis’ soon-to-be-spun-off generics unit Sandoz have generic extended-released Adderall on back order, according to a recent supply update from the American Society of Health-System Pharmacists, which tracks drug shortages. read more By Healthcare Staff Follow along with the latest monkeypox news and insights from the Fierce Healthcare team. read more By Gabrielle Masson Despite a $2.5 million check from a vaccine alliance earlier this summer, Codiak BioSciences is still struggling. The biotech is laying off around 30 employees and trimming its pipeline. read more By Andrea Park Nearly a decade after reeling in the first FDA nod allowing its deep brain stimulation technology to help treat major depressive disorder, BrainsWay has doubled back with another agency-cleared depression treatment. read more By Angus Liu Novartis is already suing a long list of generics producers that aim to bring copycats of the Swiss pharma’s popular heart failure drug Entresto to market. Now, the company itself has become target in a patent infringement lawsuit. read more By Nick Paul Taylor The hemophilia A market has a new date for the diary: Feb. 28. Officials at the FDA put the date on the agenda at Sanofi and Sobi by accepting the partners’ hemophilia A drug candidate efanesoctocog alfa for priority review. read more By Heather Landi InterWell Health completed a three-way merger with Fresenius Health Partners and Cricket Health to create a kidney care powerhouse on track to have $11 billion in costs under management by 2025. read more By Andrea Park Fundraising can be a constant headache for many health tech startups—but not for Theranica. The company has managed to keep a steady stream of financing coming in and investors interested in its technology since its 2016 founding. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
